Author

J. A. Engelman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

A. Abbasi· 1 shared A. Amzallag· 1 shared A. C. Palmer· 1 shared A. D. Sahu· 1 shared A. Dastur· 1 shared A. Friedman· 1 shared A. Langenbucher· 1 shared A. Loo· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Abbasi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A landscape of synergistic drug combinations in non-small-cell lung cancer

N. U. Nair, P. Greninger, A. Friedman, A. Amzallag, E. Cortez, A. D. Sahu, J. S. Lee, A. Dastur, R. K. Egan, E. Murchie, G. S. Crowther, J. McClanaghan, J. Boisvert, L. Damon, J. Ho, , C. H. Benes

The paper identifies synergistic drug combinations in non-small-cell lung cancer cell lines, finding that synergy often arises from sensitizing resistant models through dual pathway targeting.

bioRxiv · Jun 3, 2021 · PreprintCancer Biology

APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancer

H. Isozaki, A. Abbasi, N. Nikpour, A. Langenbucher, W. Su, M. Stanzione, H. Frisco-Cabanos, F. M. Siddiqui, N. Phan, P. Jalili, S. Oh, D. Timonina, S. Bilton, M. Gomez-Caraballo, H. L. Archibald, , A. N. Hata

This study shows that APOBEC3A mutagenesis driven by targeted therapies promotes drug resistance in non-small cell lung cancer.

bioRxiv · Jan 20, 2021Cancer Biology

Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts

A. C. Palmer, D. Plana, H. Gao, J. M. Korn, G. Yang, J. Green, X. Zhang, R. Velazquez, M. E. McLaughlin, D. A. Ruddy, C. Kowal, J. Goldovitz, C. Bullock, S. Rivera, D. Rakiec, , J. A. Williams

This study identifies biomarker-guided treatment strategies for ovarian cancer using patient-derived tumor xenografts, finding that nearly 90% of PDXs responded to at least one targeted therapy.

bioRxiv · Jan 8, 2020Cancer Biology